Biotech firm Alector's Q2 net loss narrows

Alector

07/08/2025 21:44

Overview

Alector Q2 collaboration revenue declines to $7.9 mln from $15.1 mln year-over-year

Net loss narrows to $30.5 mln from $38.7 mln in Q2 2024

Cash reserves of $307.3 mln expected to fund operations into H2 2027

Outlook

Alector expects 2025 collaboration revenue between $13 mln and $18 mln

Alector anticipates 2025 R&D expenses between $130 mln and $140 mln

Alector sees 2025 G&A expenses between $55 mln and $65 mln

Company has cash runway into the second half of 2027

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
$7.87 mln
Q2 EPS
-$0.3
Q2 Net Income
-$30.52 mln
Q2 Basic EPS
-$0.3


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and 2 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Alector Inc is $3.75, about 61.9% above its August 6 closing price of $1.43

Press Release: ID:nGNX7cZ7xk

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)